<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05034393</url>
  </required_header>
  <id_info>
    <org_study_id>LACOG 0221 - BRAVE</org_study_id>
    <nct_id>NCT05034393</nct_id>
  </id_info>
  <brief_title>Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil (LACOG 0221)</brief_title>
  <official_title>Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brazilian Breast Cancer Study Group (GBECAM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to describe in detail the patient journey from diagnosis to the beginning of&#xD;
      treatment and patterns of care of hormone receptor- positive, HER2-negative de novo or&#xD;
      recurrent metastatic breast cancer between January 2018 and December 2020 in Brazil.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of type of first-line treatment</measure>
    <time_frame>from January 2018 to December 2020</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The PFS, defined as time from treatment start until progression (by image or physical exam) or death</measure>
    <time_frame>from January 2018 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First-line treatment according to the drug name by type of health care coverage (public vs private)</measure>
    <time_frame>from January 2018 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The PFS will be evaluated by type of health care coverage (public vs private).</measure>
    <time_frame>from January 2018 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timeline from first symptom to diagnosis</measure>
    <time_frame>from January 2018 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timeline from diagnosis to molecular test</measure>
    <time_frame>from January 2018 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timeline from diagnosis to the beginning of treatment</measure>
    <time_frame>from January 2018 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' socioeconomic characteristics</measure>
    <time_frame>from January 2018 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' demographics characteristics</measure>
    <time_frame>from January 2018 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BC pathological characterization</measure>
    <time_frame>from January 2018 to December 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of diagnostic tests to define breast cancer molecular subtypes performed</measure>
    <time_frame>from January 2018 to December 2020</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with de novo or recurrent HR-positive HER2-negative mBC</arm_group_label>
    <description>Patients diagnosed with de novo or recurrent HR-positive HER2-negative mBC from January 2018 to December 2020</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study will be performed in up to 15 sites in Brazil so that the recruitment target is&#xD;
        reached within defined milestones. An adequate geographical distribution of sites within&#xD;
        Brazil will be pursued to strengthen representation of Brazilian population. Considering&#xD;
        the incidence of mBC.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women ≥18 years old&#xD;
&#xD;
          -  Histologically confirmed hormone receptor-positive HER2-negative invasive breast&#xD;
             cancer&#xD;
&#xD;
          -  Hormone receptor-positive defined as 1% to 100% of tumor nuclei positive for Estrogen&#xD;
             - - Receptor and/or Progesterone Receptor, as per ASCO/CAP Guideline 2020 - or Allred&#xD;
             score of ≥3&#xD;
&#xD;
          -  HER2-negative defined as IHC result is 0/1+ or 2+ with ISH negative as per ASCO/CAP&#xD;
             Guideline 2018&#xD;
&#xD;
          -  Diagnosed with de novo or recurrent metastatic breast cancer between January 2018 -and&#xD;
             December 2020&#xD;
&#xD;
          -  Public health system or private health system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male Breast Cancer&#xD;
&#xD;
          -  First-line treatment for mBC received through clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women histologically confirmed hormone receptor-positive HER2-negative invasive breast cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gustavo Werutsky, MD</last_name>
    <phone>+55 51 33723835</phone>
    <email>gustavo.werutsky@lacogcancerresearch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Latin American Cooperative Oncology Group (LACOG)</last_name>
    <phone>+55 51 3384 5334</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CPO</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo Werutsky, MD</last_name>
      <phone>55 51 99989 2554</phone>
    </contact>
    <investigator>
      <last_name>Gustavo Werutsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.</citation>
    <PMID>33538338</PMID>
  </reference>
  <reference>
    <citation>Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):619-626. doi: 10.1158/1055-9965.EPI-17-0627. Epub 2018 Mar 28.</citation>
    <PMID>29593010</PMID>
  </reference>
  <reference>
    <citation>Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global Cancer in Women: Burden and Trends. Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):444-457. doi: 10.1158/1055-9965.EPI-16-0858. Epub 2017 Feb 21. Review.</citation>
    <PMID>28223433</PMID>
  </reference>
  <reference>
    <citation>Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020 Aug;8(8):e1027-e1037. doi: 10.1016/S2214-109X(20)30215-1.</citation>
    <PMID>32710860</PMID>
  </reference>
  <reference>
    <citation>Lee BL, Liedke PE, Barrios CH, Simon SD, Finkelstein DM, Goss PE. Breast cancer in Brazil: present status and future goals. Lancet Oncol. 2012 Mar;13(3):e95-e102. doi: 10.1016/S1470-2045(11)70323-0. Review.</citation>
    <PMID>22381937</PMID>
  </reference>
  <reference>
    <citation>Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Vanlemmens L, Lefeuvre-Plesse C, Mathoulin-Pelissier S, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Courtinard C, Perol D, Robain M, Delaloge S. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. Eur J Cancer. 2020 Apr;129:60-70. doi: 10.1016/j.ejca.2020.01.016. Epub 2020 Mar 2.</citation>
    <PMID>32135312</PMID>
  </reference>
  <reference>
    <citation>Rosa DD, Bines J, Werutsky G, Barrios CH, Cronemberger E, Queiroz GS, de Lima VCC, Freitas-Júnior R, Couto JD, Emerenciano K, Resende H, Crocamo S, Reinert T, Van Eyil B, Nerón Y, Dybal V, Lazaretti N, de Cassia Costamilan R, de Andrade DAP, Mathias C, Vacaro GZ, Borges G, Morelle A, Caleffi M, Filho CS, Mano MS, Zaffaroni F, de Jesus RG, Simon SD. The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115). Breast Cancer Res Treat. 2020 Oct;183(3):749-757. doi: 10.1007/s10549-020-05831-y. Epub 2020 Jul 29.</citation>
    <PMID>32728860</PMID>
  </reference>
  <reference>
    <citation>Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F. Breast cancer. Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2. Review.</citation>
    <PMID>31548545</PMID>
  </reference>
  <reference>
    <citation>Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019 Jan 22;321(3):288-300. doi: 10.1001/jama.2018.19323. Review.</citation>
    <PMID>30667505</PMID>
  </reference>
  <reference>
    <citation>Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. Epub 2020 Sep 23.</citation>
    <PMID>32979513</PMID>
  </reference>
  <reference>
    <citation>André F, Neven P, Marinsek N, Zhang J, Baladi JF, Degun R, Benelli G, Saletan S, Jerusalem G. Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Curr Med Res Opin. 2014 Jun;30(6):1007-16. doi: 10.1185/03007995.2014.887002. Epub 2014 Feb 3.</citation>
    <PMID>24490834</PMID>
  </reference>
  <reference>
    <citation>Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):2-10. doi: 10.1002/pds.3891. Epub 2015 Nov 5.</citation>
    <PMID>26537534</PMID>
  </reference>
  <reference>
    <citation>von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007 Oct 16;147(8):573-7. Erratum in: Ann Intern Med. 2008 Jan 15;148(2):168.</citation>
    <PMID>17938396</PMID>
  </reference>
  <reference>
    <citation>Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019 Jul;95:103208. doi: 10.1016/j.jbi.2019.103208. Epub 2019 May 9.</citation>
    <PMID>31078660</PMID>
  </reference>
  <reference>
    <citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.</citation>
    <PMID>18929686</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

